Selecta Biosciences to Present at Canaccord Genuity Growth Conference

WATERTOWN, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies, today announced that Kei Kishimoto, Ph.D., CSO, will present at the Canaccord Genuity Growth Conference on Wednesday, August 10, 2016, at 9:30 am EDT at the InterContinental in Boston.

A live webcast will be available on the Investors & Media section of the Selecta website at www.selectabio.com. An archived replay will be available for approximately 90 days following the presentation.

About SelectaSelecta Biosciences, Inc. is a clinical-stage biopharmaceutical company developing targeted therapies that use immunomodulators encapsulated in nanoparticles to induce antigen-specific immune responses to prevent and treat disease. Selecta's proprietary Synthetic Vaccine Particle (SVP) technology is a highly flexible nanoparticle platform, capable of incorporating a wide range of antigens and immunomodulators, allowing the SVP products to either induce antigen-specific tolerance or activate the immune system.

Selecta's focus is on developing and commercializing differentiated therapies that are designed to modulate the immune system to effectively and safely treat rare diseases by mitigating the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. Tolerance-inducing SVP products also have potential applications in the treatment of allergies and autoimmune diseases.

Selecta is also developing SVP products that activate the immune system to prevent and treat cancer, infections and other diseases.

Selecta is based in Watertown, Massachusetts, USA.

For Selecta media:
Kathryn Morris
The Yates Network
+1-845-635-9828
[email protected]

For Selecta investors:
Stephanie Ascher
Stern Investor Relations, Inc.
+1-212-362-1200
[email protected]

You May Also Be Interested In

• Libra Energy Materials options two Quebec lithium projects near Cisco
• BTS Group AB (publ) Interim report January - June 2026
• BlockDAG Kicks Off Stage 1 Presale at $0.002 While DOGE and XLM Hold Key Levels! Here’s Why Buyers Are Rushing to Stack BDAG